AgomAb Therapeutics NV SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE6-KAgomAb Therapeutics NVAGMB5d

   AgomAb Therapeutics NV announces NOV-ERA study start

   • First patient dosed in NOV-ERA Phase 2b study
   • 320 patients to be enrolled globally
   • 400 mg BID dose included based on prior results
2. ROUTINE4AgomAb Therapeutics NVAGMBOct 9

   AgomAb Therapeutics NV reports insider transaction

   • David R Epstein bought 5,000 shares at $8.9
   • Insider now holds 15,000 shares directly
   • Transaction date: 10/08/2026

   David R Epstein, reporting

3. ROUTINE4AgomAb Therapeutics NVAGMBOct 8

   3 insider filings

   Tim Jasper Knotnerus, insider filing for AGMB

   Show all 3

   • 4Insider filing for AGMBOct 8
   • 4Insider filing for AGMBOct 8
   • 4Insider filing for AGMBOct 8

   Tim Jasper Knotnerus, reporting

4. ROUTINE6-KAgomAb Therapeutics NVAGMBOct 1

   Foreign issuer report

5. ROUTINE4AgomAb Therapeutics NVAGMBSep 15

   4 insider filings

   Marino Garcia, insider filing for AGMB

   Show all 4

   • 4Insider filing for AGMBSep 15
   • 4Insider filing for AGMBSep 15
   • 3New insider at AGMBSep 15
   • 3New insider at AGMBSep 15

   Marino Garcia, reporting

6. ROUTINE6-KAgomab Therapeutics NVAGMBSep 14

   Foreign issuer report

7. ROUTINE6-KAgomab Therapeutics NVAGMBSep 11

   Foreign issuer report

8. ROUTINE6-KAgomab Therapeutics NVAGMBAug 10

   Foreign issuer report

9. ROUTINE6-KAgomab Therapeutics NVAGMBAug 6

   Foreign issuer report

10. ROUTINE6-KAgomab Therapeutics NVAGMBJun 23

    Foreign issuer report

11. ROUTINE6-KAgomab Therapeutics NVAGMBMay 27

    Foreign issuer report

12. ROUTINESCHEDULE 13GAgomab Therapeutics NVAGMBMay 15

    Ownership stake disclosure by Redmile Group, LLC

    Redmile Group, LLC, filed by

13. ROUTINESCHEDULE 13GAgomab Therapeutics NVAGMBMay 15

    Ownership stake disclosure by Cormorant Asset Management, LP

    Cormorant Asset Management, LP, filed by

14. ROUTINESCHEDULE 13GAgomab Therapeutics NVAGMBMay 6

    Ownership stake disclosure by Sanofi

    Sanofi, filed by

15. ROUTINE6-KAgomab Therapeutics NVAGMBApr 24

    Foreign issuer report

16. NOTABLE20-FAgomab Therapeutics NVAGMBApr 23

    Annual report

17. ROUTINESCHEDULE 13GAgomab Therapeutics NVAGMBApr 16

    Ownership stake disclosure by Pontifax Management 4 G.P. (2015) Ltd.

    Pontifax Management 4 G.P. (2015) Ltd., filed by

18. ROUTINE3Agomab Therapeutics NVAGMBMar 18

    11 insider filings

    Pierre Thadee Victor Kemula, new insider at AGMB

    Show all 11

    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18
    • 3New insider at AGMBMar 18

    Pierre Thadee Victor Kemula, reporting

19. ROUTINES-8Agomab Therapeutics NVAGMBMar 11

    Employee stock plan registration

20. ROUTINESCHEDULE 13GAgomab Therapeutics NVAGMBMar 6

    Ownership stake disclosure by FMR LLC

    FMR LLC, filed by

21. ROUTINE6-KAgomab Therapeutics NVAGMBMar 5

    Foreign issuer report

22. NOTABLESCHEDULE 13DAgomab Therapeutics NVAGMBFeb 17

    Ownership stake disclosure by LSP 7 Cooperative UA

    7 Cooperative Ua Lsp, filed by

23. ROUTINE6-KAgomab Therapeutics NVAGMBFeb 9

    Foreign issuer report

24. ROUTINE424B4Agomab Therapeutics NVAGMBFeb 6

    Securities offering

25. ROUTINECERTAgomab Therapeutics NVAGMBFeb 5

    CERT filing

26. ROUTINE8-A12BAgomab Therapeutics NVAGMBFeb 3

    8-A12B filing

27. ROUTINEEFFECTAgomab Therapeutics NVAGMBFeb 2

    Registration declared effective

28. ROUTINEF-1/AAgomab Therapeutics NVAGMBJan 29

    Securities offering (amended)

29. NOTABLEF-1Agomab Therapeutics NVJan 16

    Securities offering

Older filings on EDGAR